Abstract
Myeloma IgE, obtained from ascitic fluid of rats previously inoculated with the IgE-producing cell line IR-162, was administered in prophylactic and therapeutic regimens to rats passively and actively sensitized to ovalbumin. Administration of myeloma IgE prior to passive sensitization resulted in approximately 95% inhibition of anaphylactic histamine release and significant protection from anaphylactic pulmonary distress. Myeloma IgE treatment prior and subsequent to active sensitization brought about a 70-80% inhibition of anaphylactic histamine release. A similar pattern of protection was seen in animals that received 5 but not 3 weekly myeloma IgE treatments subsequent to active sensitization. These findings indicate that treatment with nonspecific IgE prior to sensitization is effective in blocking anaphylactic reactions but competition with cell-bound IgE in sensitized animals requires prolonged administration of relatively large quantities of 'nonsense' IgE.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International archives of allergy and applied immunology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
